ret inhibitor Clinical Research Trials | TrialX

Loading...

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group

Any (1)

Phase 3 (1)

Interventional (1)

Blueprint Medicines Corporation (1)

No (1)

No (1)

Adult (18+) (1)

I am/have/had

I am/have/hadprogressive disease

I am/have/hadrespiratory tract diseases

I am/have/hadcancer treatment

I am/have/hadlung cancer

I am/have/hadcancer therapy

I am/have/hadlung neoplasm

I am/have/hadadenocarcinoma

I am/have/hadneoplasms by site

I am/have/hadchemoradiotherapy

I am/have/hadstage iv non-small cell lung cancer

I am/have/hadmetastatic cancer

I am/have/hadmeasurable disease

I am/have/hadlung disease

I am/have/hadcarcinoma

I am/have/hadnon-small cell lung cancer

I am/have/hadcancer

I am/have/hadmetastatic non-small cell lung cancer

I am/have/hadpulmonary disease

I am/have/hadcancer chemotherapy

I am/have/hadhead and neck neoplasms

added new label for I am/have/had

more

I am looking for

I am looking forimmunomodulators

I am looking forret inhibitor

I am looking forimmunostimulants

I am looking forpralsetinib

I am looking forpembrolizumab

I am looking forpemetrexed

I am looking forgemcitabine

I am looking forplatinum-based chemotherapy

I am looking forcisplatin

I am looking foradjuvant

I am looking forcarboplatin

I am looking forimmunomodulator

I am looking formet inhibitor

added new label for I am looking for

more

Advanced Filters

Loading...

Found 1 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

Phase 3
For Seniors
For adults
Recruiting in 100s
Interventional Study
all
Endocrinology
Recruiting

AcceleRET Lung Study of Pralsetinib for 1L RET Fusion-positive Metastatic NSCLC

This is an international, randomized, open-label, Phase 3 study designed to evaluate whether the potent and selective RET inhibitor, pralsetinib, improves outcome when compared to a platinum chemotherapy-based regimen chosen by the Investigator from a list of standard of care treatments, as measured primarily by progression free survival (PFS), for …

respiratory tract diseases

progressive disease

immunomodulators

cancer therapy

lung neoplasm

0 views
19 Feb, 2024

Congrats! You have your own personal workspace now.

Learn more

© Copyright TrialX 2024 All rights reserved.